Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy

Asan Medical Center

Status: Unknown

Conditions: Toxic Maculopathy

Treatments: Procedure: Composite Examination

Study type: Observational

Funder types: Other

Identifiers

NCT02550964

2013-0826

Details and patient eligibility

About

The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.

Enrollment: 124 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE
• Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy

Exclusion criteria

• Aged less than 19 years

Trial design

124 participants in 1 patient group

HCQ/CQ

Description:

Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.

Treatment:

Procedure: Composite Examination